S&P 500   3,963.51 (+0.75%)
DOW   33,781.48 (+0.55%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
S&P 500   3,963.51 (+0.75%)
DOW   33,781.48 (+0.55%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
S&P 500   3,963.51 (+0.75%)
DOW   33,781.48 (+0.55%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
S&P 500   3,963.51 (+0.75%)
DOW   33,781.48 (+0.55%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
NASDAQ:OCUL

Ocular Therapeutix - OCUL Stock Forecast, Price & News

$2.76
-0.04 (-1.43%)
(As of 12/8/2022 05:25 PM ET)
Add
Compare
Today's Range
$2.73
$2.88
50-Day Range
$2.79
$5.13
52-Week Range
$2.73
$7.39
Volume
409,316 shs
Average Volume
672,593 shs
Market Capitalization
$212.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.50

Ocular Therapeutix MarketRank™ Forecast

Analyst Rating
Buy
3.33 Rating Score
Upside/​Downside
425.4% Upside
$14.50 Price Target
Short Interest
Healthy
3.80% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.01
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$750,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.99) to ($0.97) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.49 out of 5 stars

Medical Sector

151st out of 1,022 stocks

Pharmaceutical Preparations Industry

57th out of 499 stocks

OCUL stock logo

About Ocular Therapeutix (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Receive OCUL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.

OCUL Stock News Headlines

Ocular Therapeutix
Minerals for Green Revolution a Massive Investor Opportunity
Demand for critical minerals needed to power green energy is expected to soar up to 40 times. China controls up to 90% of the desperately-needed supply and could throw the U.S. back into the stone age if it bans exports. One company is in hot pursuit of domestic sources with potentially big discoveries on the horizon.
Minerals for Green Revolution a Massive Investor Opportunity
Demand for critical minerals needed to power green energy is expected to soar up to 40 times. China controls up to 90% of the desperately-needed supply and could throw the U.S. back into the stone age if it bans exports. One company is in hot pursuit of domestic sources with potentially big discoveries on the horizon.
A Preview Of Ocular Therapeutix's Earnings
Ocular (OCUL) Announces Positive Data on Wet AMD Candidate
See More Headlines
Receive OCUL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.

OCUL Company Calendar

Last Earnings
11/08/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OCUL
Employees
228
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.50
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+425.4%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

Net Income
$-6,550,000.00
Net Margins
-119.35%
Pretax Margin
-119.35%

Debt

Sales & Book Value

Annual Sales
$43.52 million
Book Value
$1.15 per share

Miscellaneous

Free Float
74,238,000
Market Cap
$212.55 million
Optionable
Optionable
Beta
1.35

Key Executives

  • Mr. Antony MattessichMr. Antony Mattessich (Age 55)
    Pres, CEO & Director
    Comp: $1.04M
  • Mr. Donald Notman Jr.
    Chief Financial Officer
  • Dr. Peter K. Jarrett Ph.D. (Age 65)
    Chief Scientific Officer
  • Mr. Philip C. Strassburger (Age 62)
    Gen. Counsel
  • Mr. William H. Ransone II
    VP of Global Sales & Marketing
  • Ms. Tracy Smith
    VP of HR
  • Mr. Scott Corning
    Sr. VP of Commercial
  • Mr. Christopher G. White (Age 60)
    Chief Bus. Officer
  • Dr. Rabia Gurses Ozden M.D. (Age 54)
    Chief Medical Officer
  • Dr. Karen-Leigh Edwards M.B.A.
    Ph.D., Sr. VP of Technical Operations













OCUL Stock - Frequently Asked Questions

Should I buy or sell Ocular Therapeutix stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OCUL shares.
View OCUL analyst ratings
or view top-rated stocks.

What is Ocular Therapeutix's stock price forecast for 2023?

3 Wall Street research analysts have issued 12-month price objectives for Ocular Therapeutix's stock. Their OCUL share price forecasts range from $9.00 to $25.00. On average, they predict the company's share price to reach $14.50 in the next twelve months. This suggests a possible upside of 407.0% from the stock's current price.
View analysts price targets for OCUL
or view top-rated stocks among Wall Street analysts.

How have OCUL shares performed in 2022?

Ocular Therapeutix's stock was trading at $6.97 at the start of the year. Since then, OCUL shares have decreased by 59.0% and is now trading at $2.86.
View the best growth stocks for 2022 here
.

When is Ocular Therapeutix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our OCUL earnings forecast
.

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.03. The biopharmaceutical company had revenue of $12.15 million for the quarter, compared to analyst estimates of $12.13 million. Ocular Therapeutix had a negative net margin of 119.35% and a negative trailing twelve-month return on equity of 87.18%. During the same quarter in the prior year, the business earned ($0.17) EPS.

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

Who are Ocular Therapeutix's major shareholders?

Ocular Therapeutix's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.24%), Vanguard Group Inc. (5.13%), Deltec Asset Management LLC (3.02%), Emerald Advisers LLC (1.96%), State Street Corp (1.82%) and Emerald Mutual Fund Advisers Trust (1.41%). Insiders that own company stock include Antony C Mattessich, Opaleye Management Inc, Richard L Md Lindstrom and Summer Road Llc.
View institutional ownership trends
.

How do I buy shares of Ocular Therapeutix?

Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ocular Therapeutix's stock price today?

One share of OCUL stock can currently be purchased for approximately $2.86.

How much money does Ocular Therapeutix make?

Ocular Therapeutix (NASDAQ:OCUL) has a market capitalization of $220.25 million and generates $43.52 million in revenue each year. The biopharmaceutical company earns $-6,550,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

How many employees does Ocular Therapeutix have?

The company employs 228 workers across the globe.

How can I contact Ocular Therapeutix?

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The official website for the company is www.ocutx.com. The biopharmaceutical company can be reached via phone at (781) 357-4000, via email at chris.brinzey@westwicke.com, or via fax at 781-357-4001.

This page (NASDAQ:OCUL) was last updated on 12/8/2022 by MarketBeat.com Staff